Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $138.1667.

CORT has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. Truist Financial initiated coverage on Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $164.00 target price for the company. Weiss Ratings cut shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research note on Monday, July 27th. Finally, HC Wainwright boosted their price objective on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, July 30th.

Insider Buying and Selling

In other news, insider Roberto Vieira sold 58,333 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08. Following the transaction, the insider directly owned 4,242 shares of the company’s stock, valued at approximately $469,843.92. This trade represents a 93.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kimberly Park sold 26,685 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $122.55, for a total value of $3,270,246.75. Following the completion of the sale, the director directly owned 30,000 shares of the company’s stock, valued at approximately $3,676,500. This trade represents a 47.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 446,119 shares of company stock worth $50,644,753 over the last 90 days. Insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter worth about $1,080,964,000. First Trust Advisors LP lifted its position in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after acquiring an additional 1,480,059 shares during the period. Geode Capital Management LLC boosted its stake in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after acquiring an additional 734,646 shares in the last quarter. Norges Bank bought a new stake in Corcept Therapeutics during the fourth quarter worth about $24,213,000. Finally, Bank of New York Mellon Corp purchased a new stake in Corcept Therapeutics in the second quarter worth about $49,185,000. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $114.86 on Friday. The company’s fifty day moving average price is $108.19 and its 200-day moving average price is $74.96. The firm has a market capitalization of $12.42 billion, a price-to-earnings ratio of 273.48 and a beta of 0.45. Corcept Therapeutics has a one year low of $28.66 and a one year high of $126.38.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same period in the previous year, the firm posted $0.29 EPS. The firm’s revenue was up 31.7% compared to the same quarter last year. As a group, equities research analysts expect that Corcept Therapeutics will post 2.02 EPS for the current year.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple EPS forecasts: Estimates increased for Q4 2026 to $0.68 from $0.62, Q3 2027 to $0.78 from $0.66, FY2027 to $2.05 from $1.91, and FY2028 to $4.31 from $4.07. The upward revisions suggest improving expectations for Corcept’s long-term earnings growth. Zacks Research estimates
• Positive Sentiment: Commercial growth remains supportive: Korlym sales rose 6.2% in the first half of 2026, while the launch of Lifyorli could diversify revenue beyond the company’s established Cushing’s syndrome treatment. Will Korlym Continue to Aid CORT’s Growth Through the Rest of 2026?
• Positive Sentiment: Institutional ownership is high and buying activity continues: Several funds added to or initiated positions during the second quarter, and institutions collectively own approximately 93.6% of outstanding shares. Analysts maintain a “Moderate Buy” consensus with an average price target of $138.17. Corcept Grows to Mid-Cap on Institutional Support
• Neutral Sentiment: Corcept’s latest reported quarter exceeded expectations, with earnings of $0.36 per share versus $0.02 expected and revenue of $256.15 million, up 31.7% year over year. However, the stock trades at a very elevated earnings multiple, increasing sensitivity to any slowdown or disappointing clinical and commercial developments.
• Negative Sentiment: Insiders have recently sold shares: Director James Wilson sold 10,000 shares for approximately $1.11 million, while Joseph Lyon sold 10,000 shares for about $1.13 million. Wilson retained a substantial stake, but Lyon’s sale reduced his position by roughly 63.8%, creating a modest sentiment overhang. Insider Selling at Corcept Therapeutics

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.